Success Metrics

Clinical Success Rate
42.9%

Based on 3 completed trials

Completion Rate
43%(3/7)
Active Trials
0(0%)
Results Posted
133%(4 trials)
Terminated
4(44%)

Phase Distribution

Ph phase_2
4
44%
Ph phase_1
1
11%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

42.9%

3 of 7 finished

Non-Completion Rate

57.1%

4 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(3)
Terminated(4)
Other(2)

Detailed Status

Terminated4
Completed3
unknown2

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
42.9%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 24 (80.0%)

Trials by Status

unknown222%
terminated444%
completed333%

Recent Activity

0 active trials
Showing 5 of 9
terminatedphase_1

Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer

NCT00905021
completedphase_2

Sunitinib Non Small Cell Lung Cancer Patients Over 70

NCT00864721
terminatedphase_2

Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors

NCT01215578
terminatedphase_2

Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma

NCT00393796
terminatedphase_2

Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma

NCT01215565
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT00905021Phase 1

Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer

Terminated
NCT00864721Phase 2

Sunitinib Non Small Cell Lung Cancer Patients Over 70

Completed
NCT01215578Phase 2

Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors

Terminated
NCT00393796Phase 2

Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma

Terminated
NCT01215565Phase 2

Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma

Terminated
NCT00873210

Study In Patients With Kidney Cancer Treated With Sutent

Completed
NCT00684645

Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®

Completed
NCT00094029

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

Unknown
NCT00130897

Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9